

## **PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON LABEL**

### **1. Name of the medicinal product**

[RH039 trade name]\* Misoprostol 200 µg tablets  
Misoprostol

### **2. Statement of active substance**

Each tablet contains 200 µg misoprostol

### **3. List of excipients**

Each tablet contains hydrogenated castor oil.  
See patient information leaflet for further information.

### **4. Pharmaceutical form and contents**

1 x 4 tablets

7 x 4 tablets

15 x 4 tablets

### **5. Method and route of administration**

Oral, vaginal, sublingual or buccal use  
Read the patient information leaflet before use.

### **6. Special warning that the medicinal product must be stored out of the reach and sight of children**

Keep out of the sight and reach of children.

### **7. Other special warning(s), if necessary**

### **8. Expiry date**

EXP {MM/YYYY}

### **9. Special storage conditions**

Do not store above 30°C. Store tablets in blisters in the provided cartons.

### **10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate**

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

**11. Name and address of the supplier**

Cipla Limited  
Cipla House,  
Peninsula Business Park  
Ganpatrao Kadam Marg, Lower Parel  
Mumbai -400013,  
India  
Phone: 9122 24826000  
Fax: 9122 24826120

**12. WHO Reference Number (Prequalification Programme)**

RH039

**13. Manufacturer's batch number**

<Batch> {number}

**14. (Advice on) General classification for supply**

Medicinal product subject to medical prescription.

**15. Instructions on use**

## **MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIP**

### **1. Name of the medicinal product**

[RH039 trade name] † Misoprostol 200 µg tablets

Misoprostol

### **2. Name of the supplier**

Cipla Limited

### **3. Expiry date**

EXP {MM/YYYY}

### **4. Manufacturer's batch number**

<Batch> {number}

---

† Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.